PP
LJPC

Paloma Partners’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Paloma Partners’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-21,800
Closed -$206K – 2122
2018
Q4 		$206K Buy
+21,800
New +$328K 0.01% 1049

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Paloma Partners's LJPC Position: Q1 2019 in Review

Paloma Partners sold out of La Jolla Pharmaceutical Company (LJPC) in Q1 2019, closing a stake of 21,800 shares — an estimated $206K sold.

Paloma Partners first reported a position in LJPC in Q4 2018 and held it in 1 quarter. The position peaked at $206K in Q4 2018. 80 funds tracked by Wall St. Rank hold LJPC as of Q1 2019.

  • Paloma Partners reported no remaining La Jolla Pharmaceutical Company position as of Q1 2019 after selling out during the quarter.
  • Paloma Partners sold 21,800 La Jolla Pharmaceutical Company shares in Q1 2019, an estimated $206K.
  • Paloma Partners first reported a position in La Jolla Pharmaceutical Company in Q4 2018 and held it in 1 quarter.
  • Paloma Partners's La Jolla Pharmaceutical Company position peaked at $206K in Q4 2018.
  • 80 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.